Weekly Endocrinology Research Analysis
This week saw high-impact, cross-cutting advances: a pan-tissue single-cell Hormone Cell Atlas redefines endocrine cell networks and enables tissue-specific target discovery; a first-in-human in vivo base-editing therapy (VERVE-102) produced dose-dependent, durable PCSK9 and LDL-C reductions, signaling a potential one‑time genetic approach to lipid lowering; and translational work revealed a microbiota–melibiose–GLO1 axis mediating canagliflozin’s renoprotection, highlighting microbiome-targeted